mv-chik

Vaccineexperimental

Clinical trial activity

4 trials · 13 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0

Earliest trial started Aug 1, 2016 (NCT02861586)

Timeline

2010s

  1. Jan 1, 2016

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2016

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • mv-chik

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03807843Phase 2Mar 4, 2019Themis Bioscience GmbH, United States Army
NCT03635086Phase 2Sep 17, 2018Celerion, Themis Bioscience GmbH
NCT03028441Phase 1Dec 29, 2016National Institute of Allergy and Infectious Diseases (NIAID)
NCT02861586Phase 2Aug 1, 2016ABF Pharmaceutical Services GmbH, Assign Clinical Research GmbH, Batavia Biosciences, Biofabri, S.L, Envigo Pharma Consulting Limited, Medical University of Graz, SRI International, Themis Bioscience GmbH, University of Rostock, University of Vienna
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (13)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Themis Bioscience GmbHFor profit3312016
ABF Pharmaceutical Services GmbHFor profit1012016
Assign Clinical Research GmbHFor profit1012016
Batavia BiosciencesFor profit1012016
Biofabri, S.LFor profit1012016
CelerionFor profit1012018
Envigo Pharma Consulting LimitedFor profit1012016
Medical University of GrazAcademic/Hospital1012016
National Institute of Allergy and Infectious Diseases (NIAID)Government1112016
SRI InternationalAcademic/Hospital1012016
United States ArmyGovernment1012019
University of RostockAcademic/Hospital1012016
University of ViennaAcademic/Hospital1012016
13 organizations
Page 1 / 1